Phase III Multicenter Randomized Trial Evaluating in Patients at the Time of the Primary HIV-1 Infection, the Impact on the Viral Reservoir of a Combination Including Tenofovir/Emtricitabine and Dolutegravir or Tenofovir/Emtricitabine and Darunavir/Cobicistat
Phase of Trial: Phase III
Latest Information Update: 27 Oct 2017
At a glance
- Drugs Dolutegravir (Primary) ; Emtricitabine/tenofovir disoproxil fumarate (Primary) ; Cobicistat/darunavir
- Indications HIV-1 infections
- Focus Therapeutic Use
- Acronyms OPTIPRIM-2
- 24 Oct 2017 Planned primary completion date changed from 1 Jul 2019 to 1 Sep 2019.
- 24 Oct 2017 Status changed from not yet recruiting to recruiting.
- 13 Dec 2016 New trial record